Only one case of each of the CaBP4, STX1B, and PRIMA1 mutations has been reported globally to date; therefore, additional clinical validation is required to determine their pathogenic roles in SHE. This evidence concerns the gene CABP4 and sleep-related hypermotor epilepsy.